SpringWorks Therapeutics Inc Stock

$36.35

2.13% day before yesterday

Nasdaq, Dec 27, 10:15 pm CET

ISIN

US85205L1070

Symbol

SWTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

SpringWorks Therapeutics Inc Stock price

$36.35

-2.20 5.71% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.79 2.13%

ISIN

US85205L1070

Symbol

SWTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$2.70b
Enterprise Value	$2.33b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	17.23
P/S ratio (TTM) P/S ratio	19.96
P/B ratio (TTM) P/B ratio	5.07
Revenue (TTM) Revenue	$135.49m
EBIT (operating result TTM) EBIT	$-295.25m
Free Cash Flow (TTM) Free Cash Flow	$-209.90m
Cash position	$376.62m
EPS (TTM) EPS	$-3.73
P/E forward	negative
P/S forward	14.45
EV/Sales forward	12.47
Short interest	19.02%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

SpringWorks Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a SpringWorks Therapeutics Inc forecast:

8x Buy

100%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a SpringWorks Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from SpringWorks Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	135 135	- 100%
- Direct Costs	10 10	265% 265% 8%
Gross Profit	125 125	4,489% 4,489% 92%
- Selling and Administrative Expenses	233 233	35% 35% 172%
- Research and Development Expense	184 184	27% 27% 136%
EBITDA	-292 -292	9% 9% -216%
- Depreciation and Amortization	2.99 2.99	5% 5% 2%
EBIT (Operating Income) EBIT	-295 -295	9% 9% -218%
Net Profit	-275 -275	10% 10% -203%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

SpringWorks Therapeutics Inc Stock News

Positive

Seeking Alpha

●

13 days ago

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.

Neutral

GlobeNewsWire

●

about one month ago

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, taking place in Coral Gables, Florida on Tuesday, December 3, 2024 at 12:30 p.m. ET.

Neutral

Seeking Alpha

●

about 2 months ago

SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Kim Diamond - Vice President, Corporate Communications Saqib Islam - Chief Executive Officer Bhavesh Ashar - Chief Commercial Officer Jim Cassidy - Chief Medical Officer Francis Perier - Chief Financial Officer Badreddin Edris - Chief Operating Officer Conference Call Participan...

More SpringWorks Therapeutics Inc News

Company Profile

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. It focuses on developing drugs for underserved patient populations suffering from devastating rare diseases and cancer. Its pipeline include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

Head office	United States
CEO	Saqib Islam
Employees	305
Founded	2017
Website	www.springworkstx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now